Amphastar Pharmaceuticals (AMPH) Cash from Investing Activities (2013 - 2026)

Amphastar Pharmaceuticals has reported Cash from Investing Activities for 14 years, with the latest figure at $44.9 million in Q2 2026.

• On a quarterly basis, Cash from Investing Activities rose 7279.2% year-over-year to $44.9 million in Q2 2026; TTM through Jun 2026 was -$52.1 million, a 13.83% increase from a year earlier, with the FY2025 full-year figure at -$70.3 million, up 43.7% from the prior year.
• Cash from Investing Activities was $44.9 million for Q2 2026 at Amphastar Pharmaceuticals, up from -$16.7 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $44.9 million in Q2 2026, with the low at -$508.6 million in Q2 2023.
• Average Cash from Investing Activities over 5 years is -$47.2 million, with a median of -$16.0 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2026: Cash from Investing Activities slumped 44899.56% in 2023, then jumped 7279.2% in 2026.
• Over 5 years, Cash from Investing Activities stood at -$229000.0 in 2022, then plunged by 44899.56% to -$103.0 million in 2023, then soared by 65.38% to -$35.7 million in 2024, then sank by 69.77% to -$60.6 million in 2025, then surged by 174.08% to $44.9 million in 2026.
• The last three Cash from Investing Activities figures came in at $44.9 million (Q2 2026), -$16.7 million (Q1 2026), and -$60.6 million (Q4 2025), per Business Quant data.